Panbela Therapeutics (PBLA) Q3 2024 earnings summary

Executive summary

• Secured up to $12 million in strategic financing from Nant Capital, with $2.85 million funded and $9.15 million expected by November 15, 2024, supporting financial stability, clinical alliances, and potential immunotherapy collaborations.

• Advanced multiple clinical programs, including the pivotal Phase III ASPIRE trial in metastatic pancreatic cancer, with full enrollment expected by Q2 2025 and interim analysis in Q1 2025.

• Achieved milestones in the Flynpovi PACES trial for colorectal cancer prevention, with data readout anticipated in the second half of 2026.

• Expanded research collaborations and preclinical programs, including partnerships with MD Anderson, Vanderbilt, and ImmunityBio, and initiated new trials in ovarian, lung, and STK11 mutant NSCLC.

• Delisted from Nasdaq in April 2024; shares now quoted on OTCQB, with relisting application pending.

Financial highlights

• Net loss for Q3 2024 was $7.2 million ($1.48 per diluted share), compared to $7.8 million ($53.74 per diluted share) in Q3 2023; net loss for the nine months ended September 30, 2024, was $21.4 million.

• Research and development expenses were $6.0 million in Q3 2024, down from $6.7 million year-over-year; general and administrative expenses were flat at $1.1 million.

• Cash as of September 30, 2024, was $142,000, not including the Nant Capital funding; cash position declined from $2.6 million at year-end 2023.

• Total current assets were $5.2 million; current liabilities were $20.1 million at quarter end.

• Cash used in operations for the nine months ended September 30, 2024, was $12.5 million.

Outlook and guidance

• Interim analysis for the ASPIRE trial is expected in Q1 2025, with full enrollment by Q2 2025.

• Data readout for the PACES trial is anticipated in the second half of 2026.

• Phase II ovarian and neoadjuvant pancreatic cancer trials are planned to open in early 2025.

• Company expects to continue incurring substantial losses and negative cash flows as it advances clinical programs.

• Additional capital is required immediately to fund operations and complete clinical trials; no assurance of obtaining financing.